Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 183-186, 2003; 10.1373/49.1.183
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taieb, J.
Right arrow Articles by Lindenbaum, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taieb, J.
Right arrow Articles by Lindenbaum, A.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2003;49:183-186.)
© 2003 American Association for Clinical Chemistry, Inc.

Technical Briefs

Use of the Architect-i2000 Estradiol Immunoassay during in Vitro Fertilization

Joëlle Taieb1a, Clarisse Benattar1, Rokhaya Diop1, Anne Sophie Birr1 and Albert Lindenbaum1

1 Hôpital Antoine Béclère, Clamart, France, Department of Biochemistry and Hormonology, 157 rue de la porte de Trivaux, 92141 Clamart cedex, France

aauthor for correspondence: fax 33-1-45374745, e-mail joelle.taieb@abc.ap-hop-paris.fr

The first 300 words of the full text of this article appear below.

In women undergoing in vitro fertilization and embryo transfer (IVF-ET), serial measurements of 17ß-estradiol (E2) can be used to monitor follicular growth, and serum E2 has been shown to be correlated with the number and diameter of preovulatory follicles observed on transvaginal ultrasound scan (1)(2)(3)(4)(5)(6). The serum E2 concentration is therefore an essential variable for evaluating the progression of stimulation, adjusting daily gonadotropin therapy, predicting the optimal day for induction of ovulation [administration of human chorionic gonadotropin (hCG)] (7), preventing ovarian hyperstimulation syndrome (8)(9), and ensuring that pituitary function is adequately suppressed if a long-acting gonadoliberin-releasing hormone agonist (GnRHa) is used before stimulation (10). Another major use of E2 measurements is to evaluate ovarian function at day 3 of the menstrual cycle to determine the prognosis of IVF-ET (11).

Because results must be available within a few hours, rapid and automated assays are required. In this study, we measured E2 with a new automated assay that could be used in random, continuous access mode and assessed its usefulness for monitoring ovulation stimulation for IVF-ET.

The Architect-i2000 E2 (Abbott Laboratories) assay is a competitive two-step immunoassay based on chemiluminescent microparticle immunoassay technology and can be performed in 29 min. The ACS-180 E2 assay (Bayer Diagnostics) is a competitive one-step immunoassay based on solid-phase antigen-linked technology and chemiluminescence detection and can be completed in 15 min. The luminescence reaction and the calibration procedure are identical for the two E2 immunoassays. The two methods are linear up to 3670 pmol/L and use monoclonal antibody derived by coupling the E2 molecule at the specificity-enhancing sixth position.

The within- and between-run imprecision, detection limits, and functional sensitivities of these assays have been . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.